Prior to treatment with Adalimumab, HS patients showed significantly increased levels of iL-6, IL-8, IL-10, ESR, soluble TNF receptor II (sTNF-RII), and C-reactive protein (CRP). After treatment, the circulating levels of all of the listed inflammatory markers decreased significantly. The decrease in IL-6, IL-8, ESR, sTNF-RII, and CRP were significantly correlated with clinical improvements according to the modified HS score (mHSS). Here, IL10 is linked to histiocytic sarcoma.